Nateglinida es un agente antidiabético para el tratamiento de diabetes de tipo 2 desarrollado por la empresa suiza Novartis. Pertenece a la clase de las meglitinidas de los fármacos hipoglicemiantes.
C |
|
Chem Spider ID |
|
rdfs:comment |
|
foaf:depiction | |
Drug Bank |
|
Elimination Half-Life |
|
H |
|
Imagen |
|
In Ch I |
|
In Ch IKey |
|
foaf:isPrimaryTopicOf | |
rdfs:label |
|
Legal UK |
|
Legal US |
|
Licence EU |
|
Licence US |
|
N |
|
Nombre IUPAC |
|
Número CAS |
|
O |
|
Peso Molecular |
|
Prefijo ATC |
|
Is foaf:primaryTopic of | |
Protein Bound |
|
Pub Chem |
|
Routes Of Administration |
|
SMILES |
|
dcterms:subject | |
Sufijo ATC |
|
dbpedia-owl:thumbnail | |
UNII |
|
Verifiedrevid |
|
prov:wasDerivedFrom | |
dbpedia-owl:wikiPageExternalLink | |
dbpedia-owl:wikiPageID |
|
dbpedia-owl:wikiPageLength |
|
dbpedia-owl:wikiPageOutDegree |
|
dbpedia-owl:wikiPageRevisionID |
|
prop-latam:wikiPageUsesTemplate | |
dbpedia-owl:wikiPageWikiLink | [17 values] |
Is dbpedia-owl:wikiPageWikiLink of |